BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34643313)

  • 21. Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
    Zumsteg ZS; Morse N; Krigsfeld G; Gupta G; Higginson DS; Lee NY; Morris L; Ganly I; Shiao SL; Powell SN; Chung CH; Scaltriti M; Baselga J
    Clin Cancer Res; 2016 Apr; 22(8):2009-19. PubMed ID: 26589432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma.
    Couture C; Raybaud-Diogène H; Têtu B; Bairati I; Murry D; Allard J; Fortin A
    Cancer; 2002 Feb; 94(3):713-22. PubMed ID: 11857304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Copy number gain of PIK3CA and MET is associated with poor prognosis in head and neck squamous cell carcinoma.
    Brauswetter D; Dános K; Gurbi B; Félegyházi ÉF; Birtalan E; Meggyesházi N; Krenács T; Tamás L; Peták I
    Virchows Arch; 2016 May; 468(5):579-87. PubMed ID: 26832731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells.
    Guan L; Nambiar DK; Cao H; Viswanathan V; Kwok S; Hui AB; Hou Y; Hildebrand R; von Eyben R; Holmes BJ; Zhao J; Kong CS; Wamsley N; Zhang W; Major MB; Seol SW; Sunwoo JB; Hayes DN; Diehn M; Le QT
    Cancer Res; 2023 Mar; 83(6):861-874. PubMed ID: 36652552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RPA3 is a potential marker of prognosis and radioresistance for nasopharyngeal carcinoma.
    Qu C; Zhao Y; Feng G; Chen C; Tao Y; Zhou S; Liu S; Chang H; Zeng M; Xia Y
    J Cell Mol Med; 2017 Nov; 21(11):2872-2883. PubMed ID: 28557284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-treatment DNA Methylation From Peripheral Blood.
    Qian DC; Ulrich BC; Peng G; Zhao H; Conneely KN; Miller AH; Bruner DW; Eldridge RC; Wommack EC; Higgins KA; Shin DM; Saba NF; Smith AK; Burtness B; Park HS; Stokes WA; Beitler JJ; Xiao C
    Int J Radiat Oncol Biol Phys; 2023 Apr; 115(5):1217-1228. PubMed ID: 36410685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNAs Involvement in Radioresistance of Head and Neck Cancer.
    Ahmad P; Sana J; Slavik M; Slampa P; Smilek P; Slaby O
    Dis Markers; 2017; 2017():8245345. PubMed ID: 28325958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive capacity of FAT1 transcriptional expression in patients with head and neck squamous cell carcinomas treated with radiotherapy.
    León X; Llansana A; Pérez-Ugarte L; García J; Valero C; Quer M; Camacho M
    Acta Otorrinolaringol Esp (Engl Ed); 2023; 74(6):359-364. PubMed ID: 37931687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study.
    Kim DH; Lim ST; Kim HR; Kang EJ; Ahn HK; Lee YG; Sun S; Kwon JH; Lee SC; Lee HW; Kim MK; Keam B; Park KU; Shin SH; Yun HJ
    Oral Oncol; 2024 Apr; 151():106739. PubMed ID: 38458039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes.
    Foy JP; Bazire L; Ortiz-Cuaran S; Deneuve S; Kielbassa J; Thomas E; Viari A; Puisieux A; Goudot P; Bertolus C; Foray N; Kirova Y; Verrelle P; Saintigny P
    BMC Med; 2017 Sep; 15(1):165. PubMed ID: 28859688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prognostic mRNA expression signature of four 16q24.3 genes in radio(chemo)therapy-treated head and neck squamous cell carcinoma (HNSCC).
    Wintergerst L; Selmansberger M; Maihoefer C; Schüttrumpf L; Walch A; Wilke C; Pitea A; Woischke C; Baumeister P; Kirchner T; Belka C; Ganswindt U; Zitzelsberger H; Unger K; Hess J
    Mol Oncol; 2018 Dec; 12(12):2085-2101. PubMed ID: 30259648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of the genomic mutation signature and tumor mutation burden on relapse risk prediction in head and neck squamous cell carcinoma after concurrent chemoradiotherapy.
    Wang HC; Moi SH; Chan LP; Wu CC; Du JS; Liu PL; Chou MC; Wu CW; Huang CJ; Hsiao HH; Pan MR; Chen LT
    Exp Mol Med; 2023 May; 55(5):926-938. PubMed ID: 37121970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.
    Baba Y; Maeda T; Suzuki A; Takada S; Fujii M; Kato Y
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [MicroRNAs in Prediction of Response to Radiotherapy in Head and Neck Cancer Patients - Pilot Study].
    Ahmad P; Slavík M; Šána J; Hermanová M; Šlampa P; Smilek P; Kazda T; Slabý O
    Klin Onkol; 2018; 31(Supplementum1):137-139. PubMed ID: 29808687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel.
    Pfisterer K; Fusi A; Klinghammer K; Knödler M; Nonnenmacher A; Keilholz U
    Head Neck; 2015 Apr; 37(4):471-8. PubMed ID: 24421178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between tumour cell in vitro radiosensitivity and clinical outcome after curative radiotherapy for squamous cell carcinoma of the head and neck.
    Stausbøl-Grøn B; Overgaard J
    Radiother Oncol; 1999 Jan; 50(1):47-55. PubMed ID: 10225557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.
    Jin N; Keam B; Cho J; Lee MJ; Kim HR; Torosyan H; Jura N; Ng PK; Mills GB; Li H; Zeng Y; Barbash Z; Tarcic G; Kang H; Bauman JE; Kim MO; VanLandingham NK; Swaney DL; Krogan NJ; Johnson DE; Grandis JR
    J Clin Invest; 2021 Nov; 131(22):. PubMed ID: 34779417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of gene methylation in surgical margin imprints with locoregional recurrence in head and neck squamous cell carcinoma.
    Hayashi M; Wu G; Roh JL; Chang X; Li X; Ahn J; Goldsmith M; Khan Z; Bishop J; Zhang Z; Zhou XC; Richmon J; Agrawal N; Koch WM
    Cancer; 2015 Jun; 121(12):1957-65. PubMed ID: 25773145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive value of transcriptional expression of Krüppel-like factor-6 (KLF6) in head and neck carcinoma patients treated with radiotherapy.
    León X; Venegas M; Pujol A; Bulboa C; Llansana A; Casasayas M; Quer M; Camacho M
    Clin Transl Oncol; 2021 Dec; 23(12):2507-2512. PubMed ID: 34061320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. All-Exon TP53 Sequencing and Protein Phenotype Analysis Accurately Predict Clinical Outcome after Surgical Treatment of Head and Neck Squamous Cell Carcinoma.
    Kobayashi K; Yoshimoto S; Matsumoto F; Ando M; Murakami N; Omura G; Fukasawa M; Matsumoto Y; Matsumura S; Akamatsu M; Hiraoka N; Eigitsu R; Mori T
    Ann Surg Oncol; 2019 Jul; 26(7):2294-2303. PubMed ID: 30900104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.